Evidence map›Paper›PMID 34333128›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients.

P Heudel, B Favier, S Assaad, P Zrounba, J-Y Blay

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.Annals of oncology : official journal of the European Society for Medical Oncology · 2022
    Pooled it
  7. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. COVID-19 vaccination in cancer patients: a narrative review.The Journal of international medical research · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

P HeudelDepartment of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
B FavierDepartment of Pharmaceutical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
S AssaadDepartment of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France.
P ZrounbaDepartment of Surgery, Centre Léon Bérard Cancer Center, Lyon, France.
J-Y BlayDepartment of Medical Oncology, Centre Léon Bérard Cancer Center, Lyon, France; Lyon East Faculty of Medicine, Université Claude Bernard Lyon 1, Lyon, France; President, Unicancer, Paris, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19NeoplasmsCOVID-19 VaccinesHumansSARS-CoV-2VaccinationCOVID-19 Vaccines

Identifiers

PMID34333128
PMCPMC8321960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.